Microcolumn chromatographic immunoassays

Details Microcolumn chromatographic immunoassays Microcolumn chromatographic immunoassays

2001-05-23

2004-04-27

Le, Long V. (Department: 1641)

Chemistry: analytical and immunological testing

Involving an insoluble carrier for immobilizing immunochemicals

C436S161000, C436S524000, C435S007100, C435S007930, C210S656000

Reexamination Certificate

active

06727104

ABSTRACT:

FIELD OF THE INVENTION
The invention is directed toward an analytical method to determine the concentration of an analyte or free analyte fraction in a sample. More particularly, the method encompasses the use of chromatographic immunoassays to determine the concentration of the analyte or the free analyte fraction in a sample.
BACKGROUND OF THE INVENTION
Many drugs, hormones, and toxins exist in two distinct forms as they pass through the blood stream: 1) a fraction that is non-covalently bound to proteins or other blood components and 2) a fraction that is non-bound, or free, in solution. The free and bound fractions are present in a dynamic state, in which solutes in one state are continually exchanging with those in the other. Accordingly, in biological systems this process is constant and an equilibrium is formed between the free and bound fractions.
It has long been hypothesized that the free fraction of such substances is the biologically-active form, since it is this form which crosses cell membranes and interacts with cell receptors or other target ligands. Because the free fraction is the biologically-active form, this makes analysis of free fractions of these substances of particular interest in clinical chemistry and pharmaceutical science as a means for controlling and studying their effects within the body.
For many substances it is possible to use their total concentrations in blood or serum as estimates of their free levels by assuming there is a constant relationship between these two types of values. However, there are numerous situations where this approach does not provide meaningful, or even remotely accurate information. For example, after surgery, during malnutrition or pregnancy, and in various disease states (e.g., cancer, renal failure or liver disease) there can be a large fluctuation in the concentration of binding proteins present in blood. This can shift the equilibrium between these proteins and drugs that bind to them and concomitantly cause a change in a drug's free fraction even though its total concentration remains unaffected. Similar shifts in drug-protein binding can occur with age (e.g., in newborns or the elderly) and in situations where several drugs and/or endogenous agents compete for the same binding proteins. A drug with a high total concentration versus its binding proteins also creates problems when trying to estimate the free fraction based upon total protein concentrations since this may result in a non-linear relationship between the drug's total and free levels.
Although several analytical methods have been developed in an attempt to determine the free fraction, all of these methods are plagued with inherent inaccuracies or are lengthy and tedious to perform. Examples of these methods include equilibrium dialysis, ultrafiltration and the use of natural filtrates, such as tears or saliva. A major problem with these techniques is that the analysis often involves the use of an additional binding reagent or separation process that interacts with the free or bound fraction and causes the equilibrium between these fractions to be altered. For example, techniques with long analysis times, on the order of several seconds, results in bias in the measurement process because it allows the release of a significant amount of solutes from the bound fraction which is then detected with the original free fraction. The end result is an error in the apparent concentration of free fraction that is measured. In addition, many of these techniques suffer from non-specific interactions (e.g., binding of drugs to dialysis or filtration membranes), and are limited to only certain types of analytes (as is the case with natural filtrates).
Accordingly, a need exists to determine the free fraction without impacting the equilibrium between the free and bound fractions of the solutes. Equally, a need exists for a method that is highly specific and can be employed to determine the free fraction of a vast number of different substances.
SUMMARY OF THE INVENTION
Among the several aspects of the invention therefore, is provided a method to determine the concentration of an analyte in a sample, the method comprising applying the sample to an immunoaffinity column wherein the column separates the analyte from the sample in the millisecond time domain and then determining the analyte concentration by chromatographic immunoassay.
In yet another aspect of the invention is provided a method to determine the concentration of a free analyte fraction in a sample, the sample comprising a bound analyte fraction and the free analyte fraction, the method comprising applying the sample to an immunoaffinity column wherein the column separates the free analyte fraction from the sample in the millisecond time domain and determining the free analyte fraction concentration by chromatographic immunoassay.


REFERENCES:
patent: 4205058 (1980-05-01), Wagner et al.
patent: 4351909 (1982-09-01), Stevens
patent: 4933275 (1990-06-01), Wands et al.
patent: 4937200 (1990-06-01), Kumazawa et al.
patent: 5174959 (1992-12-01), Kundu et al.
patent: 5183740 (1993-02-01), Ligler et al.
patent: 5571729 (1996-11-01), Nakamura et al.
patent: 5595653 (1997-01-01), Good et al.
patent: 5599677 (1997-02-01), Dowell et al.
patent: 5605839 (1997-02-01), Simpson et al.
patent: 5800692 (1998-09-01), Naylor et al.
patent: 5863401 (1999-01-01), Chen
patent: 6080590 (2000-06-01), Van Der Greef et al.
patent: 6225132 (2001-05-01), Drukier et al.
patent: 6261848 (2001-07-01), Anderson et al.
Ageev et al., Derwent Acc. No. 1995-059579. SU 1832194 (Aug. 7, 1993).
Barre et al., Problems in Therapeutic Drug Monitoring: Free Drug Level Monitoring,Ther. Drug. Monitoring, 1988, pp. 133-143, vol. 10, No. 2, Raven Press.
Cassidy et al., Kinetic Chromatographic Sequential Addition Immunoassays Using Protein A Affinity Chromatography,Anal. Chem., Sep. 1992, pp/1973-77, vol. 64, Amer. Chem. Society, USA.
Cheng et al., Bovine Serum Albumin Adsorption and Desorption Rates on Solid Surfaces with Varying Surface Properties,J. Coll. Inter. Sci., Jul. 1987, pp. 212-223, vol. 118, No. 1, Academic Press, Inc.
CHIGNELL, Ligand Binding to Plasma Albumin,Handbook of Biochem.&Mol. Biol., 1976, pp. 554-582, 3d Ed., vol. II, CRC PRess, Cleveland, Ohio , USA.
de Alwis et al., Rapid Heterogeneous Competitive Electrochemical Immunoassay for IgG in the Picolmole Range,Anal. Chem., Dec. 1997, pp. 2786-2789, vol. 59, No. 23, Amer. Chem. Society.
Dombrowski et al., Investigation of Anion-Exchange and Immunoaffinity Particle-Loaded Membranes for the Isolation of Charged Organic Analytes from Water, May 1998, pp. 1969-1978. vol. 70, Amer. Chem. Society.
Fernando et al., Investigation of the Kinetic Properties by Particle-Loaded Membranes for Solid-Phase Extraction by Forced Flow Planar Chromatography,Anal. Chem., Mar. 1993, pp. 588-595, vol. 65, No. 5, Amer. Chem. Society.
Hage et al., Split-Peak Affinity Chromatographic Studies of the Immobilization-Dependent Adsorption Kinetics of Protein A,Anal. Chem., Feb. 1986, pp. 247-279, vol. 58, Amer. Chem. Society.
Hage et al., Non-Linear Elution Effects in Split-Peak Chromatography,J. Chromat., Feb. 1988, pp. 111-135, vol. 436, No. 2, Elsevier Science Publishers B.V. Amsterdam.
Hage et al., High-Performance Immunoaffinity Chromatography and Chemiluminescent Detection in the Automation of a Parathyroid Hormone Sandwich Immunoassay,Anal. Chem., Mar. 1991, pp. 586-595, vol. 69, Amer. Chem. Society.
Hage et al., Theory of a Sequential Addition Competitive Binding Immunoassay Based on High-Performance Immunoaffinity Chromatography,Anal. Chem., Jun. 1993, pp. 1622-1630, vol. 65, Amer. Chem. Society.
Hage. Immunoassays,Anal. Chem., Jun. 1993, pp. 420R-424R, vol. 65, No. 12, Amer. Chem. Society.
Hage et al., Recent advances in chromatographic and electrophooretic methods for the study of drug-protein interactions,J. Chromat., 1997, pp. 499-525, vol. 699, Elsevier Science.
Hage, Survey of recent advances in analytical applications of immunoaffinity chromatography,J. Chrom., Sep. 1998, pp. 3-28, vo

Affiliated with

Also associated with

Rating

Microcolumn chromatographic immunoassays does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Microcolumn chromatographic immunoassays, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Microcolumn chromatographic immunoassays will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3207738